ProCE Banner Activity

Updated Findings From the Phase II KarMMa Study of Idecabtagene Vicleucel for R/R Multiple Myeloma

Slideset Download
Conference Coverage
In patients with R/R MM, updated results with idecabtagene vicleucel suggest high response rates and durable responses, regardless of the number of prior therapies.

Released: June 07, 2021

Expiration: June 06, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme